Regorafenib
Also known as Stivarga (us), Regonat (india)
Regorafenib is used to treat colon and rectal cancer (cancer that begins in the large intestine or the rectum), gastrointestinal stromal tumors (GIST; a type of tumor that grows in the stomach, intestine [bowel], or esophagus [tube that connects the throat with the stomach]), and hepatocellular carcinoma (HCC; a type of liver cancer).
SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F
Based on 30 units per month. US $266.34 vs India $3.70 per unit.
The savings here are large enough that a trip may still come out ahead. Adjust the numbers to your own situation — every value is an editable estimate.
- Medicine savings over 6 months
- $47,276
- Estimated travel cost
- − $2,300
- Net savings after travel
- $44,976
Even after travel, you could come out ahead by about $44,976.
Assumptions: medicine savings = (US − India monthly price) × months. Travel cost = flights + hotel × nights + buffer. Excludes consultation fees, visas, and other costs. For information only — not medical, legal, or travel advice.
Regorafenib is filled about 5.5K times a year under Medicare Part D. At the prices above, that works out to roughly:
Rough estimate. Based on Medicare Part D prescription volume (not the entire US market) scaled by the representative monthly price — actual totals depend on dose, duration and coverage.